Objective motor assessment for PD clinical trials
Parkinson's disease motor assessment has relied on the UPDRS for decades. NeuroQuantix captures speed, pressure, smoothness, and tremor from a single drawing task — achieving AUC 0.862 for PD detection and correlating r = -0.641 with UPDRS motor scores.
The PD Motor Assessment Challenge
MDS-UPDRS Part III combines 18 items across diverse motor domains into a single composite score. A therapy that substantially improves fine motor control but does not affect gait or postural stability will show only modest composite score changes. Additionally, UPDRS SRM values of 0.3-0.5 in treatment trials require 50-100+ subjects per arm — problematic for gene therapy and rare genetic PD subtypes.
Clinical Applications
Published Evidence
Evidence from peer-reviewed publications supporting digital kinematic endpoints for parkinson's disease assessment.
CISP Composite Index
Composite Index of Speed and Pressure combines drawing velocity and pen force into a single metric that captures bradykinesia — the cardinal PD motor sign — with AUC = 0.862.
Zham P, et al. Frontiers in Neurology, 2017. DOI: 10.3389/fneur.2017.00435
Levodopa Responsiveness
Published studies demonstrate that RMSE and smoothness metrics detect levodopa on/off transitions, validating sensitivity to dopaminergic treatment effects.
Galli M, et al. J Applied Biomechanics, 2014. DOI: 10.5301/jabfm.2012.9265
Multi-Domain Capture
A single spiral task captures tremor, bradykinesia, rigidity-related pressure changes, and coordination metrics — preserving domain-specific measurement rather than averaging into a composite.
Published literature across multiple research groups
Statistical Power Advantage
Higher measurement precision translates directly into smaller enrollment requirements. See the full interactive power curve comparison on our product page.
View Power VisualizationReady to discuss parkinson's disease endpoints?
Schedule a consultation to explore how precision digital endpoints can strengthen your parkinson's disease clinical program.